Transcript Slide 1

Point of Care Testing
Quality Confab 2012
MedStar Health
‘A not-for-profit healthcare system serving Maryland and the
Washington DC region’
Maryland Hospitals:
Washington DC Hospitals:
MedStar Franklin Square Med. Center
MedStar Georgetown University Hospital
MedStar Good Samaritan Hospital
MedStar Washington Hospital Center
MedStar Harbor Hospital
MedStar National Rehabilitation Hospital
MedStar Montgomery Med Center
MedStar St. Mary’s Hospital
MedStar Union Memorial Hospital
Laboratory Teams
•
•
•
•
•
•
Chemistry
Hematology
Coagulation
Microbiology
Blood Bank
Point of Care Testing
•
•
•
•
•
•
Cytology
Anatomic Pathology
Shared Testing
Safety
Quality Assurance
Compliance
• Laboratory Advisory Council
Challenges for the POC Team
Variability Hospital to Hospital
–
–
–
–
Scope of POC Services / Test Menus
Disparate equipment
Varying clinician needs
Some have fulltime POC staff and some cover POC in addition
to other responsibilities
Aside from a common Glucometer vendor, the team
seemed to have little else to focus on as a group
Team did not function as a team
– Meetings held via conference call were poorly attended
– Members didn’t see the benefits of the team
– Members resisted bringing their issues to the group
Team Refocus 2011
Began meeting face-to-face
Developed a Team Charter
Discovered that some members had 20+ years of POC
experience while the newest POC coordinator (Gabby) had
been on the job for only 4 months.
All shared the same LIS and had similar needs for
interfaces and group purchasing advantages
Despite their differences all were challenged with:
– Meeting regulatory requirements
– Controlling “rogue’ testing
– Enforcing general policies in POC testing areas
I-STAT
PT/INR
Gabby Gets the Call
December 2011 Pharmacists from Coumadin Clinic
Expressed concerns about iSTAT INR results >4.0
# of incidents and poor correlation to the main lab
January 2012 Pharmacists still concerned
2011 – Jan 2012 Correlation reviewed
91.8% correlated
All QC, liquid and electronic reviewed
all acceptable
Instrument Performance Reviewed
1 instrument had a higher % of results >4.0
Notified Abbott Point of Care
Replaced the instrument, conducted own investigation
Notified Medical Director & POC Chair about the issue
Bobbie Gets the Call
Notifications made 4 sites using I-stat were informed
One other facility reported similar issues
Data and details were collected to look for common factors
Sites work together Correlation data was collected
All North site Coumadin clinics express concern
Data was not correlating and could not be used for dosing
Abbott begins assisting in data collection
Data causes Abbott to escalate concerns
March 2012 Abbott issues a product recall
MedStar ceases testing all PT/INR on I-Stat
POC Team Works Together
Team meets to discuss plan Patient Safety primary goal
Included Technical Experts and Coagulation team
Look back of prior reported patients
Validation of Abbott recommended software upgrade
Comparison to MedStar dosing schedules
Impact analysis of any biases before patient testing resumes
Is POC safe for our patients and coumadin dosing?
Data is gathered and reviewed
All sites actively participated in reviews & decisions
2 weeks of 100% correlations yielded hundreds of data points
100’s of patient records were reviewed with pharmacy
Coagulation experts were consulted
Technical standards were evaluated and compared
Data Compared for Safety
Before Software Upgrade --- GSH only data
Acceptability rate (POC result)
1.0-2.0
2.1-2.5
2.6-3.0
3.1-3.5
3.6-4.5
overall w/in therapeutic range
Medstar
New Criteria
91%
44%
20%
8%
0%
23%
n
11
18
20
13
6
57
< 25%
acceptability for
all patients
After Software Upgrade --- All MedStar Sites combined
Acceptability rate (POC result)
1.0-2.0
2.1-2.5
2.6-3.0
3.1-3.5
3.6-4.5
overall w/in therapeutic range
n
91
75
59
12
6
152
Medstar New
Criteria
100%
99%
95%
58%
33%
91%
< 95%
acceptability for
all patients
Decisions are made
Team evaluates data to determine SAFE limits
Standards from CLSI, Vendor and Medstar applied
CLSI +/- 0.4 difference up to 3.0 INR
Abbott +/- 20% difference
Pharmacy dosing patterns are in 0.5 INR increments
MedStar Reinstates Testing
Conservative but safe limits are defined
Pharmacy, Lab and Medical Staff agree
+/- 0.4 INR difference for INR ≤ 2.5
Within 15% agreement for INR >2.5 to 3.5
Reporting limit of 3.5
More proactive monitoring practices adopted by all
POC INR sites. Some sites opted to cease POC INR
Lessons Learned
•Team work led to improved patient safety
•Coagulation experts were instrumental in truly
understanding how data was used.
•Actual comparison biases were essential to
maintaining a safe correlation standard.
•A strict correlation factor or R value will not show
the potential dangers in dosing anti-coagulation
medications.
Going Forward
MedStar Point of Care Workgroup members have
committed themselves to understanding the clinical
use of Point of Care testing within our institutions and
to ensure that clinicians using these methods fully
understand their limitations, accuracy expectations,
and correlation to main lab methods before allowing
their use.
The MedStar POC team finally realized they have one
very important goal in common --Ensuring Patient Safety
Presenters
Bobbie Eichensehr,
QA and POC Supervisor
MedStar Point of Care Team Leader
MedStar Union Memorial Hospital
[email protected]
Marcelino Gabriel
POC Supervisor
MedStar Point of Care Team Member
MedStar Good Samaritan Hospital
[email protected]